Scarica l'app Stockscreener
7.99
0.12%
-0.010
Dopo l'orario di chiusura:
8.03
0.04
+0.50%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RLAY Giù?
Forum
Previsione
Relay Therapeutics Inc Borsa (RLAY) Ultime notizie
Will Relay Therapeutics Inc. stock deliver shareholder valueTrade Entry Report & Technical Analysis for Trade Confirmation - ulpravda.ru
Is Relay Therapeutics Inc. stock a contrarian buyJuly 2025 Fed Impact & Verified Chart Pattern Signals - ulpravda.ru
Will Relay Therapeutics Inc. stock benefit from sector rotationQuarterly Risk Review & Low Risk Profit Maximizing Plans - ulpravda.ru
Will Relay Therapeutics Inc. stock split attract more investors2025 Technical Overview & Consistent Income Trade Recommendations - ulpravda.ru
How strong is Relay Therapeutics Inc. stock balance sheetWeekly Volume Report & Daily Oversold Bounce Ideas - ulpravda.ru
Why Relay Therapeutics Inc. stock could benefit from AI revolutionWall Street Watch & Weekly High Conviction Trade Ideas - ulpravda.ru
How Relay Therapeutics Inc. stock performs in rate cut cyclesRisk Management & Low Drawdown Trading Techniques - ulpravda.ru
CEO Change: Will Relay Therapeutics Inc. stock pay special dividendsEarnings Recap Summary & Daily Entry Point Trade Alerts - ulpravda.ru
Is Relay Therapeutics Inc. stock a buy before product launchesEnergy Sector Updates & Free Professional Investment Consultations - ulpravda.ru
Why Relay Therapeutics Inc. stock could outperform in 2025Market Profile Overview & Trade Like a Pro Using AI Edge - ulpravda.ru
User | guymondailyherald.comRelay Therapeutics, Inc.Common Stock (Nasdaq:RLAY) Stock Quote - FinancialContent
Relay Therapeutics Q3 2025 Earnings Preview - MSN
What makes Relay Therapeutics Inc. stock attractive to growth funds2026 world cup usa national team round of 32 goalkeepers low block defense knockout prediction guide - ulpravda.ru
Relay Therapeutics CEO Sanjiv Patel sells $818,399 in stock - MSN
Relay Therapeutics, Inc. (RLAY) Stock Analysis: Unpacking the 72.58% Potential Upside in Precision Medicine - DirectorsTalk Interviews
Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week - MSN
Aug Action: What makes Relay Therapeutics Inc. stock attractive to growth fundsPortfolio Value Report & Weekly High Conviction Trade Ideas - moha.gov.vn
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Take Profit: Can Relay Therapeutics Inc. stock hit record highs again2025 Valuation Update & Precise Trade Entry Recommendations - moha.gov.vn
Will Relay Therapeutics Inc. stock gain from strong economyFibonacci Retracement Levels & Analyze Your Portfolio Risk in Seconds - bollywoodhelpline.com
Relay Therapeutics (NASDAQ:RLAY) Shares Up 4.9%Here's What Happened - MarketBeat
Congress Asset Management Co. Has $2.13 Million Stock Holdings in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics signals slowdown to recharge after busy year - Traders Union
Will Relay Therapeutics Inc stock pay special dividendsMarket Sentiment Report & Verified Technical Signals - moha.gov.vn
Zovegalisib’s Consistent Efficacy Across Tough Subgroups Could Be A Game Changer For Relay (RLAY) - simplywall.st
What sentiment indicators say about Relay Therapeutics Inc. stockQuarterly Market Summary & High Win Rate Trade Alerts - Улправда
Can Relay Therapeutics Inc. stock hit analyst price targets2025 Sector Review & AI Enhanced Trading Alerts - Улправда
Is Relay Therapeutics Inc. stock attractive for passive investors2025 Biggest Moves & Risk Managed Investment Entry Signals - Улправда
Can Relay Therapeutics Inc. stock resist market sell offsPortfolio Return Report & Low Risk High Reward Ideas - DonanımHaber
Can Relay Therapeutics Inc. stock hit record highs againTake Profit & High Conviction Buy Zone Picks - DonanımHaber
How Relay Therapeutics Inc. stock reacts to oil pricesTrade Performance Summary & Daily Profit Focused Stock Screening - Улправда
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares - AOL.com
Alert from Equity-Insider.com was published in error and has been withdrawn - marketscreener.com
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards - GlobeNewswire
Relay Therapeutics (NASDAQ:RLAY) Trading Up 4.7%Here's What Happened - MarketBeat
Relay Therapeutics (RLAY): Revisiting Valuation After a Sharp Rebound in 2024 - Yahoo Finance
Will Broad Zovegalisib Breast Cancer Data Reshape Relay Therapeutics' (RLAY) Targeted Oncology Narrative? - Yahoo Finance
Relay Therapeutics (NASDAQ:RLAY) Sets New 1-Year HighStill a Buy? - MarketBeat
Bellevue Group AG Boosts Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics stock hits 52-week high at 8.62 USD By Investing.com - Investing.com Australia
Wells Fargo Upgrades Relay Therapeutics (RLAY) - Nasdaq
Relay Therapeutics Reports 'Robust Activity' For Precision Breast Cancer Drug - Sahm
Why Is Relay Therapeutics Stock Gaining Friday?Relay Therapeutics (NASDAQ:RLAY) - Benzinga
RLAY Stock Receives Analyst Upgrade and Price Target Boost | RLA - GuruFocus
Relay Therapeutics stock hits 52-week high at 8.62 USD - Investing.com India
Relay Therapeutics Reports 'Robust Activity' in Study of Zovegalisib to Treat Breast Cancer - marketscreener.com
Relay Therapeutics (RLAY) Shares New Data from Zovegalisib Study - GuruFocus
Relay Therapeutics unveils efficacy subset analysis for zovegalisib at SABCS25 - Traders Union
Relay Therapeutics Reports Positive Efficacy Data for Zovegalisib in Metastatic Breast Cancer at SABCS 2025 - Quiver Quantitative
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 - Yahoo Finance
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):